Andy Chen Analyst PerformanceSenior Analyst at Wolfe ResearchAndy Chen is a stock analyst at Wolfe Research in the healthcare sector, covering 28 publicly traded companies. Over the past year, Andy Chen has issued 25 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Andy Chen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andy Chen's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings51 Last 2 YearsBuy Recommendations62.00% 31 Buy RatingsCompanies Covered28 Unique Companies Ratings Distribution50RatingsDistribution of strong buy, buy, hold, and sell ratings by Andy Chen.RatingPercentageCount Strong Buy8.0%4 ratings Buy54.0%27 ratings Hold34.0%17 ratings Sell4.0%2 ratingsOut of 50 total stock ratings issued by Andy Chen at Wolfe Research, the majority (54.0%) have been Buy recommendations, followed by 34.0% Hold, 8.0% Strong Buy, and 4.0% Sell.Best & Worst CallsBest Call0000.0%ANABFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%RNAJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ28 companiesAndy Chen, an analyst at Wolfe Research, currently covers 28 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare28 companies100.0%Andy Chen of Wolfe Research specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY26 companies92.9%PHARMACEUTICALS2 companies7.1% Andy Chen's Ratings History at Wolfe Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsROIVRoivant Sciences10/12/2026Downgrade$35.44Peer Perform$0.0000.00% ROIINSMInsmed10/12/2026Downgrade$100.60Peer Perform$0.0000.00% ROIKYMRKymera Therapeutics9/10/2026Upgrade$115.43$180.00Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals8/4/2026Upgrade$482.00$605.00Outperform$0.0000.00% ROISYRESpyre Therapeutics7/28/2026Downgrade$100.04Peer Perform$0.0000.00% ROIIONSIonis Pharmaceuticals7/16/2026Downgrade$54.73Peer Perform$0.0000.00% ROINTLAIntellia Therapeutics7/15/2026Downgrade$13.04$9.00Underperform$0.0000.00% ROISRPTSarepta Therapeutics7/9/2026Upgrade$20.21$27.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics6/10/2026Reiterated Rating$76.78Outperform$0.0000.00% ROIAVTXAvalo Therapeutics4/9/2026Initiated Coverage$14.41$48.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. DNTHDianthus Therapeutics4/9/2026Initiated Coverage$87.48$98.00Outperform$0.0000.00% ROIPALIPalisade Bio4/9/2026Initiated Coverage$1.87$7.00Outperform$0.0000.00% ROIPHVSPharvaris4/9/2026Initiated Coverage$27.56$42.00Outperform$0.0000.00% ROIAVTXAvalo Therapeutics4/8/2026Initiated Coverage$14.21$48.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics4/8/2026Upgrade$91.66Strong-Buy$0.0000.00% ROIPALIPalisade Bio4/8/2026Initiated Coverage$1.98$7.00Outperform$0.0000.00% ROIPHVSPharvaris4/8/2026Initiated Coverage$27.07$42.00Outperform$0.0000.00% ROIMLTXMoonLake Immunotherapeutics3/23/2026Upgrade$16.27$24.00Outperform$0.0000.00% ROIVERAVera Therapeutics3/11/2026Upgrade$40.25$88.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics1/7/2026Initiated Coverage$78.25Peer Perform$0.0000.00% ROIIMVTImmunovant1/6/2026Upgrade$24.97$50.00Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals1/6/2026Set Price Target$588.40$579.00$0.0000.00% ROIVRTXVertex Pharmaceuticals1/6/2026Upgrade$448.80$548.00Outperform$0.0000.00% ROIINSMInsmed12/18/2025Set Price Target$198.46$167.00Outperform$0.0000.00% ROIARGXargenex11/24/2025Reiterated Rating$918.92Peer Perform$0.0000.00% ROINTLAIntellia Therapeutics11/12/2025Reiterated Rating$10.18Peer Perform$00.0000.00% ROIAPLSApellis Pharmaceuticals11/6/2025Initiated Coverage$19.95Peer Perform$0.0000.00% ROIAKROAkero Therapeutics10/10/2025Downgrade$54.08Hold$0.0000.00% ROIALNYAlnylam Pharmaceuticals8/4/2025Upgrade$401.80Peer Perform$000.0000.00% ROIVERAVera Therapeutics8/4/2025Reiterated Rating$20.95Peer Perform$00.0000.00% ROIRNAAvidity Biosciences6/17/2025Initiated Coverage$29.80$55.00Outperform$00.0000.00% ROIBBIOBridgeBio Pharma6/17/2025Initiated Coverage$41.14$49.00Outperform$00.0000.00% ROISRPTSarepta Therapeutics6/17/2025Initiated Coverage$20.94Peer Perform$00.0000.00% ROIMLTXMoonLake Immunotherapeutics5/19/2025Upgrade$37.62$61.00Outperform$00.0000.00% ROIVRTXVertex Pharmaceuticals5/7/2025Downgrade$442.75Peer Perform$000.0000.00% ROINTLAIntellia Therapeutics4/21/2025Upgrade$7.23$21.00Outperform$00.0000.00% ROISYRESpyre Therapeutics3/18/2025Initiated Coverage$18.54$27.00Outperform$00.0000.00% ROIANABAnaptysBio2/4/2025Initiated Coverage$16.66$25.00Outperform$00.0000.00% ROICRNXCrinetics Pharmaceuticals2/4/2025Initiated Coverage$38.79Peer Perform$00.0000.00% ROIORKAOruka Therapeutics2/4/2025Initiated Coverage$13.70$20.00Outperform$00.0000.00% ROIA $247 tool for $7 (Ad)Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.See the Instant Scanner in action and claim the $7 Black Friday deal today.VERAVera Therapeutics2/4/2025Initiated Coverage$36.54$49.00Outperform$00.0000.00% ROIANABAnaptysBio2/3/2025Upgrade$16.51Strong-Buy$00.0000.00% ROIORKAOruka Therapeutics2/3/2025Upgrade$14.21Strong-Buy$00.0000.00% ROIVERAVera Therapeutics2/3/2025Upgrade$38.07Strong-Buy$00.0000.00% ROIIMVTImmunovant1/3/2025Downgrade$25.19Peer Perform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche BankBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.